IMPORTANT ANNOUNCEMENT: Regarding the Status of PHLBI and PMCfrom Executive Director Clare Cameron |
|
|
Established in 2002, the vision of The Pacific Heart, Lung & Blood Institute (PHLBI) is to rapidly develop and/or invest in early stage research into effective treatments for diseases of the heart, lungs, and blood, including rare cancers such as mesothelioma and thymus cancer. The mission of PHLBI is to generate hope through funding innovative research and education.
The Pacific Mesothelioma Center, a division of The Pacific Heart, Lung & Blood Institute, was established in 2012 with the mission of improving lives of mesothelioma patients through education on lung-sparing treatments for malignant pleural mesothelioma (MPM) and to develop and/or invest in groundbreaking research of new treatment options, in hopes of finding a cure.
The Pacific Heart, Lung & Blood Institute has a vision of holding three divisions, one for the heart, lungs and blood. Over the past 20 years, our organization has been focused on the research and treatment of malignant pleural mesothelioma (MPM).
Our goal is to one day expand our research funding and treatment capabilities toward other areas of the chest.
This aggressive cancer of the lining of the chest and abdomen, or the mesothelium, has no known cure. It is caused by exposure to asbestos, a naturally occurring mineral. For much of the 20th century, asbestos was commonly used as a thermal and electrical insulator because it is highly flame-resistant. Because of its properties, asbestos was used to manufacture countless building materials worldwide, until the 1970s when its adverse health effects became more clear.
The Pacific Mesothelioma Center funds innovative research into multi-modal mesothelioma treatment courses.
Your contribution will fund innovative, hope-restoring mesothelioma research.